Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=281 Oral Cell DNA Adducts in Smokers
Lung Cancer
Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=41 Tobacco Treatment in the Context of Lung Cancer Screening
Smoking Cessation
Primary: End of Treatment Abstinence Rates — 3; 0 Participants
N/A N=685 Improving Tobacco Treatment Rates for Cancer Patients Who Smoke
Cancer · Tobacco Use · Smoking
Primary: Intervention Ordering Rate — 113; 60 Participants
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=15 Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Electronic Cigarette Use · Smoking, Cigarette · Nicotine Dependence
Primary: Study Feasibility — 15 Participants
N/A N=231 A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
Tobacco Use
Primary: Summary of Urine Total NNAL Amount Excreted and Absolute Change From Baseline (ng/24 Hour) by Study Group and Study Day (mITT Population) — 511.889; 581.676; 548.751…
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
N/A N=16 Metabolism of NNK in Japanese Americans
Smoking
Primary: The Ratio of D4-hydroxy Acid to D4- NNAL (an Estimate if NNK Alpha Hydroxylation) — 0.133; 0.175 Ratio
N/A N=520 Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Lung Cancer
Primary: Rate of Moderate to High Arsenic Level in Cases and Controls — 0.04; 0.04 mcg/dL
Early Phase 1 N=146 Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Lung Cancer · Tobacco Use Disorder · Breast Cancer
Primary: Feasibility of a Smoking Cessation Intervention Among Cancer Patients — 55; 33 Participants
Phase 3 N=207 Extended Varenicline Treatment for Smoking Among Cancer Patients
Nicotine Dependence
Primary: 7-day CO-verified Tobacco Abstinence — 28; 32; 16; 17 participants
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=154 A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product
Tobacco Use
Primary: Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population) — 3.8; 13.8…
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=19 Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
Nicotine Dependence, Other Tobacco Product · Bladder Cancer · Lung Cancer
Primary: Change in Daily Cigarette Smoking Given 10 or More E-cigarette Sessions in a Day — 4.37 number of Daily Cigarettes
N/A N=53 Motivating a Spectrum of Cancer Patients to Quit Smoking
Cancer · Smoking
Primary: Number of Participants Who Consent to Participate in the Study- Feasibility — 53 Participants
N/A N=5 Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Lung Cancer · Prostate Cancer · Bladder Cancer
Primary: Number of Participants to Achieve Saturation in an English-language Paper Questionnaire — 30 participants
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
Phase 2 N=4 TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Squamous Cell Lung Carcinoma
Primary: Objective Response Rate (ORR) — 0 Participants
Phase 1 N=17 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
Squamous Cell Carcinoma of the Head and Neck
Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily
Phase 1 N=11 Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 3; 0 Participants
N/A N=2,146 Improving Tobacco Treatment Rates for Outpatient Cancer Patients Who Smoke
Cancer · Smoking · Tobacco Use
Primary: Penetration (Rate of Referral to TUTS or Medication Prescription) — 66; 180; 40; 222 Participants
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
N/A N=11 Brain Stimulation For Cancer Smokers
Cancer of Head and Neck · Breast Cancer · Prostate Cancer
Primary: The Number of Enrollment — 4; 4 participants
N/A N=5,123 Proactive Tobacco Treatment for Veterans
Smoking Cessation · Smoking Tobacco
Primary: Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence — 10.9; 13.5 percentage of participants — p=.02